Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.
Radioimmunoimaging and therapy has been an area of interest for several decades. Steady progress has been made toward clinical translation of radiolabeled monoclonal antibodies for diagnosis and treatment of diseases. Tremendous advances have been made in imaging technologies such as positron emission tomography (PET). However, these advances have so far eluded routine translation into clinical radioimmunoimaging applications due to the mismatch between the short half-lives of routinely used positron-emitting radionuclides such as (18)F versus the pharmacokinetics of most intact monoclonal antibodies of interest. The lack of suitable positron-emitting radionuclides that match the pharmacokinetics of intact antibodies has generated interest in exploring the use of longer-lived positron emitters that are more suitable for radioimmunoimaging and dosimetry applications with intact monoclonal antibodies. In this review, we examine the opportunities and challenges of radioimmunoimaging with select longer-lived positron-emitting radionuclides such as (124)I, (89)Zr, and (86)Y with respect to radionuclide production, ease of radiolabeling intact antibodies, imaging characteristics, radiation dosimetry, and clinical translation potential.
Nayak
Tapan K
TK
Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA.
Brechbiel
Martin W
MW
D000818:Animals; D004583:Electrons; D006207:Half-Life; D006801:Humans; D016719:Radioimmunodetection / Q000009:adverse effects / Q000191:economics / Q000379:methods* / Q000592:standards; D011868:Radioisotopes / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use
D011868:Radioisotopes